Trending Stock News

EPS for Catabasis Pharmaceuticals, Inc. (CATB) Expected At $-0.34; Carrizo Oil & Gas (CRZO) Sellers Decreased By 3.5% Their Shorts

Carrizo Oil & Gas Incorporated (NASDAQ:CRZO) had a decrease of 3.5% in short interest. CRZO’s SI was 17.68M shares in February as released by FINRA. Its down 3.5% from 18.32M shares previously. With 2.57 million avg volume, 7 days are for Carrizo Oil & Gas Incorporated (NASDAQ:CRZO)’s short sellers to cover CRZO’s short positions. The SI to Carrizo Oil & Gas Incorporated’s float is 28.84%. The stock increased 1.40% or $0.26 during the last trading session, reaching $18.85. About 724,786 shares traded. Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) has declined 34.05% since February 16, 2017 and is downtrending. It has underperformed by 50.75% the S&P500.

Analysts expect Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) to report $-0.34 EPS on March, 15.They anticipate $0.13 EPS change or 27.66% from last quarter’s $-0.47 EPS. After having $-0.31 EPS previously, Catabasis Pharmaceuticals, Inc.’s analysts see 9.68% EPS growth. The stock increased 15.83% or $0.22 during the last trading session, reaching $1.61. About 4.04M shares traded or 470.03% up from the average. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has declined 73.74% since February 16, 2017 and is downtrending. It has underperformed by 90.44% the S&P500.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $37.16 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 14 analyst reports since August 17, 2015 according to SRatingsIntel. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has “Buy” rating given on Monday, November 20 by Citigroup. The rating was maintained by Citigroup on Thursday, June 9 with “Buy”. Wedbush maintained it with “Outperform” rating and $17 target in Wednesday, June 8 report. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has “Buy” rating given on Monday, August 14 by Oppenheimer. Wedbush maintained the shares of CATB in report on Monday, August 14 with “Buy” rating. H.C. Wainwright initiated the stock with “Buy” rating in Thursday, December 22 report. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has “Neutral” rating given on Thursday, October 5 by Citigroup. The stock has “Hold” rating by Cowen & Co on Thursday, August 10. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has “Hold” rating given on Thursday, October 5 by Cowen & Co. Citigroup maintained the shares of CATB in report on Tuesday, March 22 with “Buy” rating.

Carrizo Oil & Gas, Inc., together with its subsidiaries, engages in the exploration, development, and production of gas and oil primarily in the United States. The company has market cap of $1.54 billion. The firm holds interests in gas and oil plays, including Eagle Ford Shale in South Texas; the Delaware Basin in West Texas; the Niobrara Formation in Colorado; the Utica Shale in Ohio; and the Marcellus Shale in Pennsylvania. It has a 12.95 P/E ratio. As of December 31, 2015, it had proved gas and oil reserves of 200.2 million barrels of oil equivalent; and operated 667 gross productive gas and oil wells.

Since August 14, 2017, it had 2 buys, and 2 sales for $1.45 million activity. $191,337 worth of Carrizo Oil & Gas, Inc. (NASDAQ:CRZO) shares were sold by JOHNSON S P IV. WEBSTER STEVEN A bought $909,845 worth of stock or 75,000 shares.

Leave a Reply

Your email address will not be published. Required fields are marked *